Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Thomas Powles, Mark R Lackner, Stéphane Oudard, Bernard Escudier, Christy Ralph, Janet E Brown, Robert E Hawkins, Daniel Castellano, Brian I Rini, Michael D Staehler, Alain Ravaud, Wei Lin, Bridget O'Keeffe, Yulei Wang, Shan Lu, Jill M Spoerke, Ling-Yuh Huw, Michelle Byrtek, Rui Zhu, Joseph A WareRobert J Motzer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science